|
Oct 1
|
Genentech buys Regor’s CDK inhibitors in $850m deal
|
|
Oct 1
|
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors
|
|
Sep 30
|
Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential
|
|
Sep 30
|
New weight loss drugs could be developed much faster if Roche gets its way
|
|
Sep 30
|
Roche turns to a startup in search for new breast cancer drugs
|
|
Sep 27
|
J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers
|
|
Aug 8
|
Q2 2024 Sarepta Therapeutics Inc Earnings Call
|
|
Aug 8
|
Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak
|
|
Aug 8
|
Here's Why Eli Lilly Stock Dropped 12% Last Month
|
|
Aug 8
|
Sarepta Therapeutics (SRPT) Q2 2024 Earnings Call Transcript
|
|
Aug 7
|
Heard on the Street: It Isn’t Time for Novo Nordisk to Worry About Wegovy Yet
|
|
Aug 7
|
Roche considering divesting $1.9 billion cancer data startup, FT reports
|
|
Aug 6
|
Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs
|
|
Aug 5
|
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
|
|
Aug 5
|
Regeneron (REGN) Q2 Earnings Gain From Eylea HD, Dupixent
|
|
Jul 29
|
Affimed (AFMD) to Report Q2 Earnings: What's in the Cards?
|
|
Jul 29
|
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
|
|
Jul 29
|
Swiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss
|
|
Jul 29
|
Roche acquires Point of Care technology from LumiraDx
|
|
Jul 29
|
Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care
|